Christopher Brightling discusses the effect of blocking thymic stromal lymphopoietin (TSLP) with tezepelumab in patients with moderate-to-severe uncontrolled asthma.
Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00226-5/fulltext